Get the Stockscreener App
121.17
0.89%
-1.09
After Hours:
123.00
1.83
+1.51%
Inhibrx Biosciences Inc stock is traded at $121.17, with a volume of 191.21K.
It is down -0.89% in the last 24 hours and up +45.06% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$122.26
Open:
$121.04
24h Volume:
191.21K
Relative Volume:
0.64
Market Cap:
$1.78B
Revenue:
$1.30M
Net Income/Loss:
$-130.19M
P/E Ratio:
-14.44
EPS:
-8.3898
Net Cash Flow:
$-131.94M
1W Performance:
-1.82%
1M Performance:
+45.06%
6M Performance:
+62.36%
1Y Performance:
+337.12%
1-Day Range:
$120.48
$124.19
1-Week Range:
$120.17
$129.88
52-Week Range:
$26.19
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
121.17 | 1.46B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com - Investing.com Canada
Inhibrx (INBX) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Available Record; Trading Response: The Market Price Declines 2.92% in the Available RecordNegative Surprise Momentum - vinanet.vn
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx (INBX) Q1 2026 Results: EPS Falls Short of Its Estimate in the Current Update; Market Move: The Stock Gains 7.25% at the CloseEarnings Stability Report - vinanet.vn
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Elevated Pipeline InvestmentReturn On Capital - vinanet.vn
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - Stock Traders Daily
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) Falls 8.9% to $88.37 as Downside Pressure BuildsUp Down Ratio - Vinanet
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Inhibrx Biosciences (INBX) Slides 8% to $89.22: Support at $84.76 Becomes Key TestNHNL Divergence - vinanet.vn
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - MarketBeat
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Inhibrx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data - Stock Titan
Inhibrx Reports Second Quarter 2026 Financial Results - PR Newswire
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart - Stock Titan
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold" - MarketBeat
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday - MarketBeat
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
Healthcare of Ontario Pension Plan Trust Fund Sells 93,300 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800 - TradingKey
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P. - MarketBeat
TradingKey - TradingKey
Inhibrx Biosciences Inc (INBX) Balance Sheet - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences (INBX) Declines 4% as Stock Pulls Back From Resistance ZoneChaikin Flow - Vinanet
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Reports Operating LossesBuyback Announcement Report - Vinanet
INBX Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesReturn On Assets - Vinanet
Inhibrx Biosciences (INBX) Faces Headwinds as Stock Dips 1.89% – Support Test AheadChandelier Stop - dars.gov.et
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):